Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. (Q35067737)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Timothy M Pawlik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ralph H Hruban

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Christopher L Wolfgang

object named as

Christopher L Wolfgang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

John L Cameron

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Richard D Schulick

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Barish H Edil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ross C Donehower

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Daniel A Laheru

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Laura D Wood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Michael A Choti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Amanda L Blackford

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ana De Jesus-Acosta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Amy Hacker-Prietz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Katherine Y Fan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Susannah Ellsworth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Joseph M Herman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Aaron T Wild

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lei Zheng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Dung T Le

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

English

0 references

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

678-685

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer

3 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Erlotinib in lung cancer - molecular and clinical predictors of outcome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Selected cancers with increasing mortality rates by educational attainment in 26 states in the United States, 1993-2007.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322929

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23773391

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/23773391

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23773391

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.IJROBP.2013.03.032

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

23773391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23773391%20AND%20SRC:MED&resulttype=core&format=json